SIC
PLX icon

SJS Investment Consulting’s Protalix BioTherapeutics PLX Stock Holding History

SJS Investment Consulting’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$70 Buy
+30
New +$64 ﹤0.01% 2671

Other funds holding PLX

SOADOR
State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return
HIM
Harbour Investment Management Edmonds, Washington $194M AUM 15.93% 1-Year Est. Return
OGF
Orin Green Financial San Diego, California $271M AUM 20.78% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

SJS Investment Consulting's PLX Position: Q2 2026 in Review

SJS Investment Consulting opened a new position in Protalix BioTherapeutics (PLX) in Q2 2026: 30 shares worth $70. The stake represents ﹤0.01% of the portfolio and ranks #2671 among its holdings.

9 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

  • SJS Investment Consulting held 30 shares of Protalix BioTherapeutics worth $70 as of Q2 2026.
  • Protalix BioTherapeutics was a new SJS Investment Consulting position in Q2 2026.
  • Protalix BioTherapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #2671 holding.
  • 9 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.